文献速递冠心病

风险分层模型在当代非ST段抬高型急性冠脉综合征管理中的作用与相关性

Role and relevance of risk stratification models in the modern-day management of non-ST elevation acute coronary syndromes.
PubMed 文献 · Heart · 2023-03-10

本文综述国际指南关于NSTE-ACS风险分层的推荐,并讨论未来新风险模型的发展方向。NSTE-ACS患者异质性大,指南推荐使用经过验证的风险预测模型识别高危患者以指导个体化治疗,但现有证据基于过时的人群特征、诊断阈值和治疗方案,对女性和衰弱老年人适用性有限,且未纳入关键预后变量,导致基线风险估计不准确。因此当前风险模型已不再适用,需要能反映不同人群 demographics、高敏肌钙蛋白检测和当代治疗选择的风险预测评分。

要点

  • NSTE-ACS患者短期和长期结局差异大,统一标准化治疗无效且不合适。
  • 国际指南推荐使用经过验证的风险预测模型识别高危患者,以指导个体化治疗。
  • 现有风险模型基于过时证据,对女性和衰弱老年人适用性有限,且未捕获关键预后变量。

核心结论

  • 当前风险模型已不再适用,需要能反映不同人群特征、高敏肌钙蛋白检测和当代治疗选择的新风险预测评分。

研究设计与样本

  • 本文为综述,总结国际指南关于NSTE-ACS风险分层的推荐,并讨论未来新风险模型的发展方向。

主要发现

  • NSTE-ACS占英国急性冠脉综合征表现的大部分,但该组患者的管理策略数十年来一直是争论主题。
  • NSTE-ACS患者短期和长期临床结局差异大,使得统一标准化治疗方法无效且不合适。
  • 现代研究显示,提供早期更强效的治疗可改善特别高不良结局风险患者的结局。
  • 现有证据基于过时的人群特征、不同的诊断阈值和过时的治疗,对女性和衰弱老年人适用性有限。
  • 当前风险模型未捕获关键预后变量,导致对患者基线风险估计不准确及后续治疗不当。

关键数值与推荐

  • 国际指南推荐通过使用经过验证的风险预测模型来识别高不良结局风险患者,从而采用个体化治疗方法。

临床怎么用

  • 临床应使用经过验证的风险预测模型识别NSTE-ACS高危患者,以指导个体化治疗决策。
  • 需认识到现有风险模型对女性和衰弱老年人适用性有限,并关注其未捕获的关键预后变量。

局限性

  • 现有证据基于过时的人群特征、不同的诊断阈值和过时的治疗。
  • 证据对女性和衰弱老年人适用性有限。
  • 当前风险模型未捕获关键预后变量,导致基线风险估计不准确和后续治疗不当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We summarise the international guidelines surrounding risk stratification as well as discuss new emerging data for future development of a new risk model in the management of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS). NSTE-ACS accounts for the bulk of acute coronary syndrome presentations in the UK, but management strategies in this group of patients have remained a subject of debate for decades. Patients with NSTE-ACS represent a heterogeneous population with a wide variation in short-term and long-term clinical outcomes, which makes a uniform, standardised treatment approach ineffective and inappropriate. Studies in the modern era have provided some guidance in treating this subset of patients: the provision of early, more potent therapies has been shown to improve outcomes in patients at a particularly elevated risk of adverse outcomes. International guidelines recommend adopting an individualised treatment approach through the use of validated risk prediction models to identify such patients at high risk of adverse outcomes. The present available evidence, however, is based on dated demographics, different diagnostic thresholds and outdated therapies. In particular, the evidence has limited applicability to female patients and older people with frailty. Moreover, the current risk models do not capture key prognostic variables, leading to an inaccurate estimation of patients' baseline risk and subsequent mistreatment. Therefore, the current risk models are no longer fit for purpose and there is a need for risk prediction scores that account for different population demographics, higher sensitivity troponin assays and contemporary treatment options.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Balasubramanian, Mills, Wilkinson, et al. Role and relevance of risk stratification models in the modern-day management of non-ST elevation acute coronary syndromes. Heart. 2023. PMID: 36104217. doi:10.1136/heartjnl-2022-321470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。